Related Experiment Video
Updated: Aug 14, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Recombinant Tri-Segmented Pichinde Virus as a Novel Live Viral Vaccine Platform
Rekha Dhanwani1,2, Hinh Ly1, Yuying Liang3
1Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, 1988 Fitch Ave., Ste 295, Animal Science/Veterinary Medicine Building, Saint Paul, MN, 55108, USA.
Abstract:
Pichinde virus (PICV) is a nonpathogenic arenavirus with a bi-segmented RNA genome (L and S segments) that encodes four viral genes. We have developed a reverse genetics system to generate recombinant tri-segmented PICV (rP18tri) that packages three RNA segments (L, S1, and S2) and can encode up to two foreign genes. Using influenza virus HA and NP as model antigens, we show that the rP18tri vector can induce strong humoral and cell-mediated immunity, which further increases upon a booster dose. We propose that this novel rP18tri vector can be developed into a useful vaccine platform for other antigens, particularly when strong cellular immunity and prime-boost vaccination strategy are desired.

